April2006PHARMACOLOGICANDPHARMACOKINETICASPECTSOFFGIDS1423
PreclinicalPharmacology,
Pharmacokinetics,andToxicologyRequiredforNovelTherapeuticAgents
Thissectionoutlinessomegeneralpharmacody-namic,pharmacokinetic,andsafetyaspectsthatareim-portantforthedevelopmentofnewdrugsforFGIDs.
ThePharmacodynamicTarget
Drugselectivity.Selectivityreferstotheabilityof
acompoundtointeractwithonlyonereceptorsubtype,leavingotherreceptorsunaffectedatconcentrationsachievedatclinicallyuseddosesandavoidingsideef-fects.Althoughthisde nitionwasconsideredkeyto ndingeffectiveneworexperimentalmedications,thereareseveralimportantpitfallsinthisapproach.
First,drugselectivityisarelativeconcept,andthetendencytolabeladrugasa“selective”ligandforagivenreceptorsubtypeignoresthefactthatasinglemolecule,attherapeuticdoses,mayhaveseveral,sometimesdiffer-ent,biologicaltargets.Forinstance,cisapridewasfoundtobeapartial5-HT4receptoragonist,20a5-HT3recep-torantagonist,andafairlypotentHERGK channelblocker.21
Thesecondpitfallisthat,becauseofthemultifactorialpathophysiologyofFGIDs,single-receptormodulatingdrugsmaybelesslikelytoachieveasubstantialthera-peuticgain.Inseveral elds,22evidencesuggeststhatbalancedmodulationofmultipletargetsmayprovideasuperiortherapeuticeffectandsideeffectpro lecom-paredwiththeactionofaselectiveligand.Rationalapproachesinwhichstructuralfeaturesfromselectiveligandsarecombinedhaveproduceddesignedmultipleligandsthatspanalargevarietyoftargets.22Akeychallengeinthedesignofaligandwithmultipleactionsistoachieveabalancedpotencyandactivityateachtargetofinterestandasuitablepharmacokineticpro le.Thelessselectivealigandis,theharderitistopredicttoxicity;oncetoxicityoccurs,itbecomesevenmoredif culttoprovideamechanisticexplanationforit.Thismayjeopardizethedevelopmentandregulatoryapprovalofsuchalessselectiveligand.
Third,itislikelythatthemechanismsresponsibleforsymptomsinFGIDsmaydifferfromonepatienttoanotherandasingletargetmaynotachieveadequateef cacyinapatientpopulation.Withtheselectiveap-proachtorelievingsymptomsorgroupsofsymptoms(eg,painandconstipationordiarrhea),experienceshowsthatprimaryclinicalendpointswereachievedin 70%ofpatientswithagentssuchastegaserodoralos-etron.23–25Thelackofef cacyisunlikelytore ectan
inadequatedosebecausephase2studiesdidnotsuggestahigherdosewasmoreeffective;hence,thereistheneedtoconsiderusingmultipletherapiesor“designed”mul-tipleligandstoenhancethebene t/riskratio.Forin-stance,a5-HT3receptorantagonistwithpartialagonistactionat5-HT4receptorsmaybelessconstipatingthanapure5-HT3receptorantagonist.Anotherexampleisprovidedbytachykininreceptorantagonists;ithasbeensuggestedthattheanalgesicef cacyandmotilityinhi-bitionofmulti-tachykininorpan-tachykininreceptorantagonistsaresuperiortothatofmonoreceptorantagonists.26,27
Pharmacodynamicversuspathophysiologictar-get.Whendrugstargetasinglereceptormechanism,
heterogeneityinpathophysiology(eg,dysmotilityvshy-persensitivity)hasanegativeimpactonthetherapeuticgainifpatientsarenotselectedonthebasisofthespeci cdisorder.Indeed,someofthedisappointingresultsofthepastdecadecanbeattributedtotheheterogeneityoffunctionaldisorders,lackofunderstandingofpathophys-iology,andlackofshort-termmechanisticstudiesthatcanpredictclinicaloutcome.Newdrugsshouldtargettheentirepathophysiologicmechanism(s)contributingtothefunctionaldisorderratherthanonlyanindividualpartoraspeci creceptor.Thus,nonselectiveagentsdesignedtomodulatemultipletargetsofthewholepathophysiologicprocess(eg,dysmotility,sensorydisor-der,in ammation)wouldbeadvantageousoverhighlyselectivemedicationsaddressingasinglemechanism.Appropriatepatientsubgroupsshouldberecruitedtoshowthetherapeuticpropertiesofamedication,al-thoughthismayreducethegeneralizabilityoftheresultsofthetrial.
Pharmacokinetics
Pharmacokineticsmayhelptoachievegutselec-tivity.Thisapproachisparticularlyrelevantwhentherearepotentialactionsoutsidethegut.Forexample,pe-ripherallyrestrictedopioidreceptorantagonistssuchasmethylnaltrexoneandalvimopandonotcrosstheblood-brainbarrierand,inaddition,haveveryloworalbio-availability.28,29Thisoffersthepotentialtomodulateintestinalmotilitywithoutsystemiceffects.Moreover,targeteddrugdeliverytothecolonwithpH-ortime-dependentrelease30,31orbacterialactivationofaprodrugofferpotentialnewapproachesforFGIDs.
Anotherimportantpharmacokineticpropertyisthelackofinteractionswithfoodorotherdrugs.CYP2D6(10%slowmetabolizersinthecommunity),CYP3A4,andCYP2C19areimportantisoenzymesbecauseoftheirinvolvementinthemetabolismofmanydrugsanddrug-druginteractions.Signi cantinteractionswiththeseen-
Functional Gastrointestinal Disorders -- New Answers to Old Questions Lin Chang, MD Introduction While much progress has been made in recent years in the ...
GASTROENTEROLOGY 2006;130:1435–1446 Gender, Age, Society, Culture, and the Patient’s Perspective in the Functional Gastrointestinal Disorders LIN CHANG,*,...
Table 1. Functional Gastrointestinal Disorders C. Functional bowel disorders C1. Irritable bowel syndrome C2. Functional bloating C3. Functional constipation ...
Table 1. Functional Gastrointestinal Disorders F. Functional anorectal disorders F1. Functional fecal incontinence F2. Functional anorectal pain F2a. Chronic ...
Review Articles Functional Gastrointestinal Disorders: An Update for the Psychiatrist MICHAEL P. JONES, M.D., MICHAEL D. CROWELL, PH.D. KEVIN W. OLDEN...
Functional Gastrointestinal Disorders A. Functional esophageal disorders A1. Functional heartburn A2. Functional chest pain of presumed esophageal origin A3. ...
Among these, functional gastrointestinal disorders (FGIDs) are predominant: a heterogeneous group of chronic diseases that are believed not to have structural ...
弛不够或排便时推进力不足的客观证据 Rome III: the functional gastrointestinal disorders Drossman DA. 2006: 639 便秘严重程度的判断依据便秘及有关症状轻重度...
胃肠动力中药的研究 王平 wangping0632@yahoo.com.cn 功能性胃肠病 (functional gastrointestinal disorders, FGID) 胃肠动力性疾病 (disorders of gastrointestinal ...
热门文档